WithdrawnPhase 4

Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation

Stopped: Investigator decided not to move forward with study prior to study start date

United States0Started 2019-12

Plain-language summary

Type 2 diabetes is a chronic disease that has reached epidemic proportions. In order to improve our strategies for preventing and treating type 2 diabetes the investigators need to better understand the mechanism of this disease, and the way in which current therapies, such as the drug liraglutide, work to control blood sugar. It is known that liraglutide acts via increasing the secretion of the hormone insulin from the pancreas, hormone that in turn controls blood sugar. However, it is not known whether liraglutide also has actions on the liver. Animal studies have suggested that liraglutide might act by controlling the liver enzyme glucokinase (GCK), an enzyme that increases blood sugar uptake by the liver. This could be a crucial mechanism in which liraglutide controls blood sugar independently of insulin, thus making it beneficial not only in type 2 but also in type 1 diabetes. The effect of liraglutide on GCK activity has not been yet measured in humans. The investigators propose to investigate the acute and chronic effect of liraglutide on GCK by using a simple, widely used procedure (an IntraVenous Glucose Tolerance Test-IVGTT) and a novel approach (mathematical modeling of data obtained from this procedure), to assess GCK activity in people with type 2 diabetes. The investigators will first compare data obtained form 2 IVGTTs (with and without liraglutide) performed 1 week apart (acute effect). The investigators will then give liraglutide to patients for 6 weeks and do another IVGTT to measure GCK activity (chronic effects). Data obtained from this study will be used to further understand the mechanism of liraglutide action and how to better employ our current therapeutic options and develop new strategies for preventing and treating diabetes.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18- 65 years of age (inclusive) * Ability to provide informed consent before any trial-related activities * Ability to communicate effectively with research staff * Ability to return for follow up visit * Adequate IV access * If a female of childbearing potential, non-pregnant and taking reliable contraception * Documented T2DM (per most recent American Diabetes Association criteria); * Drug naïve or treated with metformin only; * Diabetes should be well controlled (as defined by HbA1 ≤ 7.5%, FPG \<180 mg/dl). Exclusion Criteria: * Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures * Presence of cancer or any clinically significant cardiac, respiratory, renal, hepatic, gastrointestinal, endocrinological, haematological, neurological, or psychiatric diseases or disorders (inclusion will be discussed with attending physician) * Liver disease; history of alcoholism. * Known or suspected allergy to liraglutide * Contraindications to liraglutide: patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 * Patients with a history of pancreatitits * Patients that have been treated with drugs that promote weight loss (e.g., Xenical® \[orlistat\], Meridia® \[sibutramine\], Acomplia® \[rimonabant\], Acutrim® \[phenylpropanolamine\], or similar over-the-counter medications) within 3 months of study start * Patients that have b…

What they're measuring

Liver glucokinase activity (acute effect)

Timeframe: 12 months

Liver glucokinase activity (chronic effect)

Timeframe: 12 months

Trial details

NCT IDNCT02198209

SponsorCedars-Sinai Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-07